Long-Term Clinical Outcomes of Patients Receiving Proton Beam Therapy for Caudate Lobe Hepatocellular Carcinoma

Takashi Iizumi (iizumi@pmrc.tsukuba.ac.jp)  
University of Tsukuba Hospital  https://orcid.org/0000-0001-6632-4356

Toshiyuki Okumura  
University of Tsukuba Faculty of Medicine: Tsukuba Daigaku Igaku Iryokei

Yuta Sekino  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Hiroaki Takahashi  
Mayo Clinic Rochester

Yu-Lun Tsai  
Cathay General Hospital

Daichi Takizawa  
Hitachi General Hospital

Toshiki Ishida  
Ibaraki Prefectural Central Hospital

Yuichi Hiroshima  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Masatoshi Nakamura  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Shosei Shimizu  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Takashi Saito  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Haruko Numajiri  
University of Tsukuba Hospital: Tsukuba Daigaku Fuzoku Byoin

Masashi Mizumoto  
University of Tsukuba Faculty of Medicine: Tsukuba Daigaku Igaku Iryokei

Kei Nakai  
University of Tsukuba Faculty of Medicine: Tsukuba Daigaku Igaku Iryokei

Hideyuki Sakurai  
University of Tsukuba Faculty of Medicine: Tsukuba Daigaku Igaku Iryokei
Abstract

Background

Hepatocellular carcinoma (HCC) located in the caudate lobe (caudate HCC) is rare; however, patients with this type of tumour have poorer prognoses than do those with HCC in other segments. Despite many published reports on the clinical usefulness of proton beam therapy (PBT) for HCC, data on the clinical outcomes of patients undergoing PBT for caudate HCC remain scarce. Therefore, the present study aimed to investigate the outcomes of this group of patients.

Methods

Thirty patients with caudate HCC who underwent definitive PBT between February 2001 and February 2014 were retrospectively analysed. The total irradiation doses ranged from 55 to 77 (median 72.6) Gy relative biological dose.

Results

The median follow-up period was 37.5 (range, 3.0–152.0) months. The overall survival rates at 1, 3, and 5 years were 86.6%, 62.8%, and 46.1%, respectively. According to univariate and multivariate analyses, Child-Pugh A (P < 0.01), having a single tumour (P = 0.02), and a low serum alpha-fetoprotein level (P < 0.01) were significant factors predicting longer survival. The local control rates at 1, 3, and 5 years were 100.0%, 85.9%, and 85.9%, respectively, while the corresponding progression-free survival rates were 65.0%, 27.5%, and 22.0%, respectively. No grade 3 or worse adverse events were observed.

Conclusions

PBT is effective and safe for the treatment of caudate HCC, and should therefore be considered a feasible option for intervention in patients with this disease.

Introduction

Liver cancer, which most often presents as hepatocellular carcinoma (HCC), constitutes the sixth most common type of malignancy and the fourth leading cause of cancer-related deaths worldwide [1]. Despite recent developments in surveillance programs for patients with risk factors for HCC, many individuals are still diagnosed at more advanced stages [2]. HCC located in the caudate lobe (caudate HCC) is relatively rare and has a poorer prognosis than HCC in other lobes owing to the involvement of the portal vein and/or inferior vena cava (IVC); this facilitates tumour spread both intra- and extra-hepatically early in the course of the disease [3].

Surgical resection is considered a first-line curative treatment for caudate HCC given its efficacy [4–13]. However, hepatic resection of caudate HCC is technically challenging and maintains high complication and tumour recurrence rates given that the lesion is embedded between the hepatic hilum and IVC [4, 14].
Moreover, cirrhotic liver and poor functional reserve, which are commonly observed among patients with HCC, also render the surgery difficult [10]. Non-surgical treatments, including percutaneous ablation therapies such as radiofrequency ablation (RFA), are also challenging because of the narrow percutaneous puncture window and adjacent major vessels [14]. The existence of several branches of feeding arteries also complicate the treatment of caudate HCC using transcatheter hepatic arterial chemoembolization (TACE) [15–17]. The caudate lobe is also considered the most dangerous hepatic zone for targeting with stereotactic body radiation therapy (SBRT), especially when main portal vein tumour thrombosis (PVTT) occurs [18].

Proton beam therapy (PBT) has the ability to deposit high amounts of energy over a very short distance with no exit dose [19, 20], and is widely used for the treatment of various kinds of cancers owing to this unique advantage. Patients with HCC can benefit from PBT given that it spares a large volume of the unaffected liver from low to moderate doses of radiation, which would elevate the risk of radiation-induced liver disease [2, 21]. Previous studies have shown PBT to be useful for achieving good local control with tolerable adverse events for the treatment of HCC [22–26]. Several studies have also reported that PBT is beneficial for the treatment of HCC with PVTT [27, 28] or inferior vena cava tumour thrombosis (IVCTT) [29, 30]. However, to date, information on the clinical outcomes of patients who receive PBT for caudate HCC is limited; there has only been a case report discussing radiation therapy for the treatment of this type of HCC [31]. The purpose of this study was to evaluate the clinical outcomes of patients who received PBT for caudate HCC.

**Materials And Methods**

**Study population**

Between February 2002 and February 2014, a total of 973 patients with HCC underwent PBT at our hospital. Fifty-two patients with inoperable caudate HCC were consecutively treated, among whom 30 received definitive treatment and were included in this study. Treatment was considered definitive if all visible tumours were included in the clinical target volume. All study procedures involving human participants were conducted according to the ethical standards of the institutional research committee under the principles of the Declaration of Helsinki or its equivalent. This retrospective analysis was approved by the institutional review board of our hospital (R01-167). Written informed consent was originally obtained from every patient before the start of treatment, but such consent was waived for the current study.

**Proton beam therapy**

Metallic fiducial markers were implanted into the liver parenchyma beside the tumour under ultrasound guidance. Surgical clips and/or lipiodol accumulation were substituted for fluoroscopically detectable fiducial markers that were present in patients who were previously treated for HCC. All patients underwent simulation computed tomography (CT) with respiratory synchronisation during the expiratory phase at 2.5 or 5 mm intervals in the treatment position [32], and these data were directly transferred to a
The clinical target volume was delineated by including visible tumours with a 5–10 mm margin. An aperture margin of 5.5–14 mm and an additional 0–5 mm margin in the caudal axis direction were added to encompass the entire clinical target volume. Proton beams ranging from 155 to 250 MeV, generated through a linear accelerator and synchrotron, were spread out and shaped with ridge filters, double-scattering sheets, multi-leaf collimators, and a custom-made bolus to conform to the treatment planning data [33]. The proton beam was synchronised to the end-expiratory phase by a respiratory gating system, which is a laser range finder that monitors the movement of the patient’s body surface caused by respiratory motion. The irradiation dose was calculated by multiplying the physical dose (Gy) by the relative biological effectiveness (RBE) and was expressed as Gy (RBE), under the assumption that a proton RBE value relative to high-energy photons was 1.1.

**Treatment**

The PBT treatment doses are summarised in Table 1. A total dose of 72.6 Gy (RBE) in 22 fractions was delivered in most cases (70.0%). While the majority of patients had received other treatments prior to undergoing PBT, 11 newly diagnosed patients were also included (36.7%).

**Follow-up and toxicity evaluation**

Serum alpha-fetoprotein (AFP) and/or des-gamma-carboxy prothrombin (DCP) measurements were obtained for all patients every 2–4 months after completion of PBT. The patients also underwent abdominal CT or magnetic resonance imaging as long as they remained in good condition. Toxicity was evaluated using the Common Terminology Criteria for Adverse Events version 4.0.

**Statistical analysis**

Continuous data are expressed as medians. Overall survival (OS), local control (LC), and progression-free survival (PFS) curves were constructed using the Kaplan-Meier method. OS, LC, and PFS were calculated as the intervals between the first day of PBT and death, local recurrence, and disease progression, respectively, or else were censored at the time of the last follow-up. Univariate and multivariate Cox regression analysis were used to identify clinical factors that were of independent prognostic significance. All statistical analyses were performed using the R software, version 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria, https://R-project.org). Differences were considered significant when the P-value was < 0.05.

**Results**

**Baseline patient characteristics**

The median follow-up period was 37.5 (range, 3.0–152.0) months, and the median patient age was 67 (range, 50–83) years. The patients were predominantly male (86.7%). Twenty-four patients (80.0%) were
classified as Child-Pugh A (i.e., scores of 5 and 6). Four patients (13.3%) were classified as Child-Pugh B, and 1 (3.3%) as Child-Pugh C; the Child-Pugh score of 1 patient with atrial fibrillation could not be assessed owing to the use of warfarin. The median tumour size was 2.3 cm; a majority of patients (76.7%) had a solitary tumour although 7 (23.3%) had multiple tumours. Five patients had vascular invasion. The median AFP level was 26.5 ng/mL and that of DCP was 59.0 mAU/mL. The baseline patient and tumour characteristics are summarised in Tables 2 and 3.

Survival, local control, and progression-free survival

The patients’ clinical outcomes are shown in Fig. 1. The OS rates at 1, 3, and 5 years were 86.6%, 62.8%, and 46.1%, respectively. According to univariate and multivariate analyses, Child-Pugh A status (HR = 4.83; 95% confidence interval [CI], 1.52–15.4; P < 0.01), having a single tumour (HR = 3.73; 95% CI, 1.28–10.31; P = 0.02), and serum AFP levels below the median of 26.5 ng/mL (HR = 4.07; 95% CI, 1.52–10.92; P < 0.01) were significant predictors of longer survival (Table 4). The LC rates at 1, 3, and 5 years were 100.0%, 85.9%, and 85.9%, respectively, while the corresponding PFS rates were 65.0%, 27.5%, and 22.0%, respectively.

Toxicity

Acute grade 1–2 dermatitis was observed in most patients (n = 17, 56.7%). Grade 1 nausea and grade 2 abdominal bloating were observed in 1 patient (3.3%). In terms of late toxicities, grade 2 ascites was observed in 1 patient (3.3%), and grade 1 pneumonitis and hyperpigmentation were observed in 1 (3.3%) and 3 (10.0%) of the patients, respectively. No grade 3 or worse acute or late toxicities were observed (Table 5).

Discussion

Treatment of caudate HCC is technically challenging regardless of whether surgical resection or nonsurgical interventions (including percutaneous ablation therapy, TACE, and SBRT) are used. Moreover, clear evidence has not been established for the treatment of caudate HCC because of its rarity. While previous studies demonstrated that PBT is a promising treatment option for HCC, those that specifically focus on PBT for caudate HCC are scarce. To the best of our knowledge, there is only a single case report describing the treatment of caudate HCC; this intervention included SBRT [31]. In the present study, we investigated the survival, tumour control, and adverse events in patients with caudate HCC who were treated with PBT; as such, this was the first study of its kind.

Our observed 1-, 3-, and 5-year OS rates were 86.6%, 62.8%, and 46.1%, respectively. In Mizumoto et al.’s investigation of the clinical outcomes of 266 patients with HCC who received PBT between 2001 and 2007 [24], the 1-, 3-, and 5-year OS rates were 87%, 61%, and 48%, respectively, while the corresponding PFS rates were 56%, 21%, and 12%, respectively. They also reported that the 1-, 3-, and 5-year LC rates were 98%, 87%, and 81%, respectively. Although the background factors of that study (which was performed at our institution) may be different from those in the current study (rendering exact comparisons impossible), the clinical outcomes in patients of both studies were comparable even though
the previous investigation included patients with HCCs located in other segments of the liver parenchyma.

The mainstay of treatment for caudate HCC is surgical resection. However, owing to the anatomical complexity of the caudate lobe, the procedure is challenging and carries a higher risk of complications than conventional hepatectomy. This is particularly true if tumour invasion into the surrounding vessels (causing PVTT and IVCTT) occurs. Additionally, resection of the caudate lobe is not indicated for patients with poor liver functional reserve. The reported 3- and 5-year OS rates for patients who underwent surgical treatment for caudate HCC were 34.0–90% and 25.9–76.0%, respectively [4, 5, 7, 10–13, 34–36]. In our study, the corresponding OS rates were 62.8% and 46.1%, respectively; our cohort included 4 patients with major vascular invasion (2 with PVTT [one Vp3 and the other Vp4] and 2 with IVCTT). Given that the prognosis of patients who undergo surgical resection for caudate HCC is generally worse than that of patients who undergo surgery for lesions in other segments, our results suggest that the effectiveness of PBT for the former group may be comparable to that of surgery. Complications such as blood loss and liver decompensation are major risks when opting for surgical treatment in patients with caudate HCC; however, we observed manageable acute and late toxicities, none of which were grade 3 or higher. As such, PBT appears to be a suitable modality for the treatment of caudate HCC given its acceptable survival rates and tolerable adverse events.

Despite their low complication rates, the main setback of performing percutaneous ablation therapy for caudate HCC is the high rates of tumour recurrence compared with HCCs in other segments [37–40]. A higher local tumour progression rate after RFA for caudate HCC is presumably associated with the difficulty of positioning the needle electrode owing to the narrow percutaneous puncture and the surrounding major vessels [14, 36, 37]. The cooling effect from the major vessels adjacent to the caudate lobe, known as the heat sink effect, has the potential to weaken the coagulation produced by RFA and result in tumour recurrence [36, 37]. The OS rates for patients who underwent percutaneous ablation therapies for caudate HCC at 3 and 5 years were reported to be 31.3–74.0% and 11.2–21.9%, respectively [14, 15, 39, 41–43], which are worse than those reported in patients whose lesions are in other hepatic segments [44]. Effective TACE for caudate HCC is also technically challenging owing to the presence of multiple feeding arteries, and the tumour recurrence rate is high [15, 16, 45]. Previous studies found a high LC rate (> 80%) following PBT for HCC performed in patients since 1980 [21]. In the current study, we confirmed that the caudate HCC LC rate at 5 years remained high (85.9%), indicating that PBT ought to be considered for the treatment of caudate HCC.

This study had several limitations. First, it included a mix of patients with naive and recurrent HCC, and most (63.3%) had undergone several rounds of prior treatments. Second, this was a retrospective study conducted at a single institution. Third, the number of patients was relatively small owing to the rarity of the studied condition. As such, selection bias may have occurred. However, given that caudate HCC is rare, data from retrospective studies with small sample sizes can be used to establish treatment data. Although our research indicated that PBT might be a promising option for the definitive treatment of caudate HCC, further studies with a larger number of patients from multiple institutions are required.
Conclusions

Our results indicate that PBT is effective and tolerable for patients with caudate HCC. Child-Pugh A, the presence of a single tumour, and low serum AFP levels are favourable prognostic factors. Therefore, PBT may be a promising treatment option for patients with caudate HCC.

Abbreviations

- **AFP** alpha-fetoprotein
- **CT** computed tomography
- **DCP** des-gamma-carboxy prothrombin
- **Gy** gray
- **HCC** hepatocellular carcinoma
- **IVC** inferior vena cava
- **IVCTT IVC** tumor thrombosis
- **LC** local control
- **OS** overall survival
- **PBT** proton beam therapy
- **PFS** progression-free survival
- **PVTT** portal vein tumour thrombosis
- **RBE** relative biological effectiveness
- **RFA** radiofrequency ablation
- **TACE** transcatheater hepatic arterial chemoembolization

Declarations

Ethics approval and consent to participate

This retrospective analysis was approved by the institutional review board of our hospital (R01-167). Written informed consent was originally obtained from every patient before the start of treatment, but such consent was waived for the current study.
Consent for publication
Not applicable

Availability of data and material
The raw data used in this study are available from the corresponding author upon reasonable request.

Competing interests
The authors have no conflict of interest to declare.

Funding
This research was supported by AMED under Grant Number 20ck0106485h0002 in the writing of this report.

Author contributions
TI made substantial contributions to the study concepts and design of this study, acquisition and statistical analysis of data, literature research and manuscript preparation and is a guarantor of integrity of the entire study. TO made substantial contributions to interpretation of data and manuscript preparation and editing. HS made substantial contributions to interpretation of data, manuscript editing and the final approval of the version to be published. YS, HT, Y-LT, and DT made substantial contributions to the study concepts and design and acquisition, analysis and interpretation of data. TI, YH, MN, and SS also made substantial contributions to interpretation of data. TS, HN, MM and KN made contributions to manuscript editing. All authors read, approved the final manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.

Acknowledgements
The authors would like to acknowledge Masaru Sato, who assisted in establishing the data collection system for this research. We would also like to thank Editage (www.editage.com) for English language writing. This research was supported by AMED under Grant Number 20ck0106485h0002.

References
[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492.

[2] Yeung RH, Chapman TR, Bowen SR, Apisarnthanarax S (2017) Proton beam therapy for hepatocellular carcinoma Expert Rev Anticancer Ther 17:911–24. https://doi.org/10.1080/14737140.2017.1368392.
[3] Takayasu K, Muramatsu Y, Shima Y, Goto H, Moriyama N, Yamada T, et al (1986) Clinical and radiologic features of hepatocellular carcinoma originating in the caudate lobe Cancer 58:1557–62. https://doi.org/10.1002/1097-0142(19861001)58:7<1557::aid-cncr2820580729>3.0.co;2-e.

[4] Tanaka S, Shimada M, Shirabe K, Maehara SI, Tsujita E, Taketomi A, et al (2005) Surgical outcome of patients with hepatocellular carcinoma originating in the caudate lobe. Am J Surg 190:451–5. https://doi.org/10.1016/j.amjsurg.2004.12.005.

[5] Yamamoto T, Kubo S, Shuto T, Ichikawa T, Ogawa M, Hai S, et al (2004) Surgical strategy for hepatocellular carcinoma originating in the caudate lobe. Surgery 135:595–603. https://doi.org/10.1016/j.surg.2003.10.015.

[6] Yang MC, Lee PH, Sheu JC, Lai MY, Hu RH, Wei CK (1996) Surgical treatment of hepatocellular carcinoma originating from the caudate lobe. World J Surg 20:562–6. https://doi.org/10.1007/s002689900087.

[7] Ikegami T, Ezaki T, Ishida T, Aimitsu S, Fujihara M, Mori M (2004) Limited hepatic resection for hepatocellular carcinoma in the caudate lobe. World J Surg 28:697–701. https://doi.org/10.1007/s00268-004-7341-4.

[8] Hawkins WG, DeMatteo RP, Cohen MS, Jarnagin WR, Fong Y, D'Angelica M, et al (2005) Caudate hepatectomy for cancer: A single institution experience with 150 patients. J Am Coll Surg 200:345–52. https://doi.org/10.1016/j.jamcollsurg.2004.10.036.

[9] Chaib E, Ribeiro MAF Jr, de S Collet e Silva F, Saad WA, Cecconello I (2007) Surgical approach for hepatic caudate lobectomy: Review of 401 cases. J Am Coll Surg 204:118–27. https://doi.org/10.1016/j.jamcollsurg.2006.09.020.

[10] Sakoda M, Ueno S, Kubo F, Hiwatashi K, Tateno T, Kurahara H, et al (2009) Surgery for hepatocellular carcinoma located in the caudate lobe. World J Surg 33:1922–6. https://doi.org/10.1007/s00268-009-0110-7.

[11] Nagasue N, Kohno H, Yamanoi A, Uchida M, Yamaguchi M, Tachibana M, et al (1997) Resection of the caudate lobe of the liver for primary and recurrent hepatocellular carcinomas. J Am Coll Surg 184:1–8.

[12] Takayama T, Makuuchi M (1998) Segmental liver resections, present and future-caudate lobe resection for liver tumors. Hepatogastroenterology 45:20–3.

[13] Peng SY, Li JT, Liu Y Bin, Cai XJ, Mou YP, Feng XD, et al (2006) Surgical treatment of hepatocellular carcinoma originating from caudate lobe--a report of 39 cases. J Gastrointest Surg 10:371–8. https://doi.org/10.1016/j.gassur.2005.09.026.
[14] Liu B, Long J, Wang W, Huang T, Xie X, Chen S, et al (2019) Predictive factors of treatment outcomes after percutaneous ablation of hepatocellular carcinoma in the caudate lobe: A retrospective study. BMC Cancer 19:699. https://doi.org/10.1186/s12885-019-5881-0.

[15] Terayama N, Miyayama S, Tatsu H, Yamamoto T, Toya D, Tanaka N, et al (1998) Subsegmental transcatheter arterial embolization for hepatocellular carcinoma in the caudate lobe. J Vasc Interv Radiol 9:501–8. https://doi.org/10.1016/s1051-0443(98)70307-0.

[16] Miyayama S, Yamashiro M, Yoshiie Y, Nakashima Y, Ikeno H, Orito N, et al (2010) Hepatocellular carcinoma in the caudate lobe of the liver: Variations of its feeding branches on arteriography. Jpn J Radiol 28:555–62. https://doi.org/10.1007/s11604-010-0471-8.

[17] Takahashi H, Mori K, Sekino Y, Okumura T, Hiyama T, Fukuda K, et al (2019) Angiographic findings in patients with hepatocellular carcinoma previously treated using proton beam therapy. J Oncol 2019:4–10. https://doi.org/10.1155/2019/3580379.

[18] Wang PM, Chung NN, Hsu WC, Chang FL, Jang CJ, Scorsetti M (2015) Stereotactic body radiation therapy in hepatocellular carcinoma: Optimal treatment strategies based on liver segmentation and functional hepatic reserve. Reports Pract Oncol Radiother 20:417–24. https://doi.org/10.1016/j.rpor.2015.03.005.

[19] Bortfeld T, Schlegel W (1996) An analytical approximation of depth - dose distributions for therapeutic proton beams for therapeutic proton beams. Phys Med Biol 41:1331. https://doi.org/10.1088/0031-9155/41/8/006

[20] Lawrence JH, Tobias CA, Born JL, Linfoot JA, Kling RP, Gottschalk A (1964) Alpha and proton heavy particles and the Bragg Peak in Therapy. Trans Am Clin Clim Assoc 75:111–6.

[21] Mizumoto M, Oshiro Y, Okumura T, Fukumitsu N, Numajiri H, Ohnishi K, et al (2016) Proton beam therapy for hepatocellular carcinoma: A review of the University of Tsukuba Experience. Int J Part Ther 2:570–8. https://doi.org/10.14338/ijpt-15-00035.2.

[22] Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23:1839–46. https://doi.org/10.1200/JCO.2005.00.620.

[23] Fukumitsu N, Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Abei M, et al (2009) A prospective study of hypofractionated proton beam therapy for patients with hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 74:831–6. https://doi.org/10.1016/j.ijrobp.2008.10.073.

[24] Mizumoto M, Okumura T, Hashimoto T, Fukuda K, Oshiro Y, Fukumitsu N, et al (2011) Proton beam therapy for hepatocellular carcinoma: A comparison of three treatment protocols. Int J Radiat Oncol Biol Phys 81:1039–45. https://doi.org/10.1016/j.ijrobp.2010.07.015.
[25] Sanford NN, Pursley J, Noe B, Yeap BY, Goyal L, Clark JW, et al (2019) Protons versus photons for unresectable hepatocellular carcinoma: Liver decompensation and overall survival. Int J Radiat Oncol Biol Phys 105:64–72. https://doi.org/10.1016/j.ijrobp.2019.01.076.

[26] Cheng JY, Liu CM, Wang YM, Wang YM, Hsu HC, Huang EY, et al (2020) Proton versus photon radiotherapy for primary hepatocellular carcinoma: a propensity-matched analysis. Radiat Oncol15:1–10. https://doi.org/10.1186/s13014-020-01605-4.

[27] Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, et al (2009) Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185:782–8. https://doi.org/10.1007/s00066-009-2020-x.

[28] Lee SU, Park JW, Kim TH, Kim YJ, Woo SM, Koh YH, et al (2014) Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Strahlenther Onkol 190:806–14. https://doi.org/10.1007/s00066-014-0604-6.

[29] Mizumoto M, Tokuuye K, Sugahara S, Hata M, Fukumitsu N, Hashimoto T, et al (2007) Proton beam therapy for hepatocellular carcinoma with inferior vena cava tumor thrombus: Report of three cases. Jpn J Clin Oncol 37:459–62. https://doi.org/10.1093/jjco/hym038.

[30] Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, et al (2020) Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol 146:711–20. https://doi.org/10.1007/s00432-019-03096-7.

[31] Chung Y-K, Hwang S, Ko G-Y, Yoon SM (2018) Long-term complete response after transcatheter arterial chemoembolization and stereotactic body radiation therapy in a patient with hepatocellular carcinoma at the caudate lobe. Ann Hepato-Biliary-Pancreatic Surg 22:274. https://doi.org/10.14701/ahbps.2018.22.3.274.

[32] Fukumitsu N, Ishida M, Terunuma T, Mizumoto M, Hashimoto T, Moritake T, et al (2012) Reproducibility of image quality for moving objects using respiratory-gated computed tomography: A study using a phantom model. J Radiat Res 53:945–53. https://doi.org/10.1093/jrr/rrs039.

[33] Inada T, Hayakawa Y, Ohara K, Maruhashi A, Hiramatsu Y, Akisada M (1983) High energy proton beam for the management of cancer [Article in Japanese]. Nihon Igaku Hoshasen Gakkai Zasshi 43:781–93.

[34] Liu P, Yang JM, Niu WY, Kan T, Xie F, Li DQ, et al (2010) Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol 16:1123–8. https://doi.org/10.3748/wjg.v16.i9.1123.

[35] Abdel Wahab M, Fathy O, Elhanafy E, Atif E, Sultan AM, Salah T, et al (2011) Caudate lobe resection for hepatocellular carcinoma. Hepatogastroenterology 58:1904–8. https://doi.org/10.5754/hge11324.
[36] Sakamoto Y, Nara S, Hata S, Yamamoto Y, Esaki M, Shimada K, et al (2011) Prognosis of patients undergoing hepatectomy for solitary hepatocellular carcinoma originating in the caudate lobe. Surgery 150:959–67. https://doi.org/10.1016/j.surg.2011.03.005.

[37] Nishigaki Y, Tomita E, Hayashi H, Suzuki Y, Iritani S, Kato T, et al (2013) Efficacy and safety of radiofrequency ablation for hepatocellular carcinoma in the caudate lobe of the liver. Hepatol Res 43:467–74. https://doi.org/10.1111/j.1872-034X.2012.01095.x.

[38] Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–40. https://doi.org/10.1148/radiol.2281020718.

[39] Peng ZW, Liang HH, Chen MS, Zhang YJ, Li JQ, Zhang YQ, et al (2008) Percutaneous radiofrequency ablation for the treatment of hepatocellular carcinoma in the caudate lobe. Eur J Surg Oncol 34:166–72. https://doi.org/10.1016/j.ejso.2007.08.004.

[40] Liu B, Long J, Wang W, Huang G, Jiang C, Zhang X, et al (2018) Treatment of hepatocellular carcinoma in the caudate lobe: US-guided percutaneous radiofrequency ablation combined with ethanol ablation. Clin Radiol 73:647–56. https://doi.org/10.1016/j.crad.2018.02.017.

[41] Shibata T, Maetani Y, Ametani F, Kubo T, Itoh K, Konishi J (2002) Efficacy of nonsurgical treatments for hepatocellular carcinoma in the caudate lobe. Cardiovasc Intervent Radiol 25:186–92. https://doi.org/10.1007/s00270-001-0111-x.

[42] Lu CL, Wu JC, Chiang JH, Lui WY, Chau GY, Lee SD (1997) Hepatocellular carcinoma in the caudate lobe: Early diagnosis and active treatment may result in long-term survival. J Gastroenterol Hepatol 12:144–8. https://doi.org/10.1111/j.1440-1746.1997.tb00397.x.

[43] Lee BC, Liu KL, Wu CH, Huang KW, Ho CM, Hu RH, et al (2018) Comparison of radiofrequency ablation and transarterial chemoembolization for hepatocellular carcinoma in the caudate lobe. Cardiovasc Intervent Radiol 41:1699–707. https://doi.org/10.1007/s00270-018-1978-0.

[44] Kudo M, Izumi N, Kubo S, Kokudo N, Sakamoto M, Shiina S, et al (2020) Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 50:15–46. https://doi.org/10.1111/hepr.13438.

[45] Kim H-C, Chung JW, Jae HJ, Yoon J-H, Lee J-H, Kim YJ, et al (2010) Caudate lobe hepatocellular carcinoma treated with selective chemoembolization. Radiology 257:278–87. https://doi.org/10.1148/radiol.10100105.

Tables

Table 1. Treatment doses received by the patients (n = 30)
| Total dose Gy (RBE)/fraction | Count |
|-----------------------------|-------|
| 55 Gy (RBE)/10 fraction     | 1 (3.3%) |
| 60 Gy (RBE)/15 fraction     | 1 (3.3%) |
| 72.6 Gy (RBE)/22 fraction   | 21 (70.0%) |
| 74 Gy (RBE)/37 fraction     | 5 (16.7%) |
| 77 Gy (RBE)/35 fraction     | 2 (6.7%) |

Table 2. The basic characteristics of the patients (n = 30)

Abbreviations: Gy, gray; RBE, relative biological effectiveness
| Characteristic                              | Value         |
|--------------------------------------------|---------------|
| **Age (years), median (range)**            | 67 (50–83)    |
| **Sex**                                    |               |
| Male                                       | 26 (86.7%)    |
| Female                                     | 4 (13.3%)     |
| **Performance status score**               |               |
| 0                                          | 12 (40.0%)    |
| 1                                          | 17 (56.7%)    |
| 2                                          | 1 (3.3%)      |
| **Child-Pugh classification**              |               |
| A (5)                                      | 17 (56.7%)    |
| A (6)                                      | 7 (23.3%)     |
| B (7)                                      | 3 (10.0%)     |
| B (8)                                      | 1 (3.3%)      |
| C (11)                                     | 1 (3.3%)      |
| NA                                         | 1 (3.3%)      |
| **Underlying cause**                       |               |
| HBV                                        | 8 (26.7%)     |
| HCV                                        | 16 (53.3%)    |
| HBV and HCV                                | 1 (3.3%)      |
| Non-HBV/HCV                                | 5 (16.7%)     |

Abbreviations: NA, not applicable; HBV, hepatitis B virus; HCV, hepatitis C virus.

**Table 3. Characteristics of the tumours of the patients**
| Size (cm), median (range) | 2.3 (1.0–9.0) |
|--------------------------|----------------|
| **Number**               |                |
| Single                   | 23 (76.7%)     |
| Multiple                 | 7 (23.3%)      |
| **Number of previous treatments** |       |
| None                     | 11 (36.7%)     |
| One                      | 7 (23.3%)      |
| Two                      | 3 (10.0%)      |
| Three or more            | 9 (30.0%)      |
| **Vascular invasion**    |                |
| None                     | 25 (83.3%)     |
| Vp3                      | 2 (6.7%)       |
| Vp4                      | 1 (3.3%)       |
| IVCTT                    | 2 (6.7%)       |
| **Tumour marker**        |                |
| AFP, median (range), ng/mL | 26.5 (1–16861.3) |
| DCP, median (range), mAU/mL | 59 (11–168890) |

Abbreviations: Vp3, right or left portal vein; Vp4, main trunk; IVCTT, inferior vena cava tumour thrombosis; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin
| Variables                                      | Univariate |                     | Multivariate |                     |
|-----------------------------------------------|------------|---------------------|--------------|---------------------|
|                                               | HR  95% CI | P-value  | HR  95% CI | P-value  |
| Performance status score (0 vs 1–2)           | 1.53 0.58–4.00 | 0.39    | 13.79 3.35–56.8 | <0.01   |
| Child-Pugh (A vs B/C)                         | 4.83 1.52–15.4 | <0.01  | 13.79 3.35–56.8 | <0.01   |
| Vascular invasion (none vs Vp3–4/IVCTT)       | 1.64 0.53–5.07 | 0.39    |              |         |
| Age (≥67 vs <67 years, the median)            | 2.15 0.85–5.42 | 0.11    |              |         |
| Sex (male vs female)                          | 1.41 0.46–4.30 | 0.55    |              |         |
| Maximum tumour diameter (≥2.3 vs <2.3 cm, the median) | 1.37 0.56–3.40 | 0.49    |              |         |
| Number of tumours (solitary vs multiple)      | 3.73 1.28–10.91 | 0.02    | 4.49 1.31–15.35 | 0.02   |
| Serum AFP level (≥26.5 vs <26.5 ng/mL, the median) | 4.07 1.52–10.92 | <0.01  | 4.92 1.66–14.56 | <0.01   |
| Serum DCP level (≥59 vs <59 mAU/mL, the median) | 0.82 0.34–1.99 | 0.66    |              |         |
| Previous treatment status (naïve vs recurrent) | 0.70 0.27–1.79 | 0.45    |              |         |

Abbreviations: Vp3-4, main, right, or left portal vein; IVCTT, inferior vena cava tumour thrombosis; AFP, alpha-fetoprotein; DCP, des-gamma-carboxy prothrombin; HR, hazard ratio; CI, confidence interval

| Table 5. Toxicities experienced by the patients (n = 30) |
| Acute                          | Grade       |
|-------------------------------|-------------|
|                               | 1 | 2 | 3 or higher |
| Dermatitis                    | 15 | 2 | 0 |
| Abdominal bloating            | 0 | 1 | 0 |
| Nausea                        | 1 | 0 | 0 |

| Late                          | Grade       |
|-------------------------------|-------------|
|                               | 1 | 2 | 3 or higher |
| Hyperpigmentation             | 3 | 0 | 0 |
| Ascites                       | 0 | 1 | 0 |
| Pneumonitis                   | 1 | 0 | 0 |